ArticleCancer immunology, immunotherapy : CII2025

Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Hao Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.